ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility
ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility GlobeNewswire July 01, 2025 RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low serum testosterone No FDA-approved oral therapies currently exist for this underserved population LAUSANNE, Switzerland and COPENHAGEN, Denmark, […]